Table 2.
HRs of Ischemic Arterial Disease, CHD, and Stroke Events by SSH Level in Postmenopausal Women of the 3C Case–Cohort Study
| Ischemic Arterial Disease* | CHD | Ischemic Stroke | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age Adjusted | Adjusted‡ | Age Adjusted | Adjusted‡ | Age Adjusted | Adjusted‡ | ||||||||||||||||
| SSH Level | No. of Events | HR | 95% CI | P† | HR | 95% CI | P† | No. of Events | HR | 95% CI | P† | HR | 95% CI | P† | No. of Events | HR | 95% CI | P† | HR | 95% CI | P† |
| Total estradiol, pg/mL | |||||||||||||||||||||
| For 1 SD log | 106 | 1.39 | (1.13–1.72) | <0.01 | 1.42 | (1.12–1.79) | <0.01 | 67 | 1.43 | (1.11–1.86) | <0.01 | 1.49 | (1.10–2.02) | 0.01 | 39 | 1.35 | (0.95–1.92) | 0.08 | 1.34 | (0.95–1.89) | 0.08 |
| Q1 <3.51 | 19 | 1 | [reference] | 0.02 | 1 | [reference] | <0.05 | 12 | 1 | [reference] | 0.07 | 1 | [reference] | 0.12 | 7 | 1 | [reference] | 0.10 | 1 | [reference] | 0.13 |
| Q2 [3.51–5.27] | 20 | 1.33 | (0.66–2.66) | 1.46 | (0.70–3.09) | 14 | 1.46 | (0.62–3.42) | 1.55 | (0.61–3.93) | 6 | 1.09 | (0.35–3.35) | 1.30 | (0.40–4.26) | ||||||
| Q3 [5.27–7.83] | 31 | 1.71 | (0.91–3.23) | 1.84 | (0.90–3.76) | 19 | 1.71 | (0.77–3.78) | 1.72 | (0.70–4.25) | 12 | 1.75 | (0.67–4.58) | 2.17 | (0.73–6.46) | ||||||
| Q4 ≥7.83 | 36 | 1.99 | (1.06–3.73) | 1.99 | (0.96–4.10) | 22 | 1.98 | (0.90–4.35) | 2.08 | (0.81–5.32) | 14 | 2.00 | (0.77–5.15) | 1.95 | (0.70–5.42) | ||||||
| Bioavailable estradiol, pg/mL | |||||||||||||||||||||
| For 1 SD log | 106 | 1.38 | (1.12–1.70) | <0.01 | 1.42 | (1.12–1.78) | <0.01 | 67 | 1.45 | (1.11–1.88) | <0.01 | 1.50 | (1.11–2.04) | <0.01 | 39 | 1.30 | (0.93–1.82) | 0.13 | 1.32 | (0.94–1.84) | 0.11 |
| Q1 <2.32 | 18 | 1 | [reference] | 0.02 | 1 | [reference] | 0.05 | 12 | 1 | [reference] | 0.05 | 1 | [reference] | 0.10 | 6 | 1 | [reference] | 0.18 | 1 | [reference] | 0.20 |
| Q2 [2.32–3.56] | 25 | 1.83 | (0.92–3.63) | 2.03 | (0.96–4.26) | 15 | 1.66 | (0.70–3.94) | 1.76 | (0.68–4.54) | 10 | 2.56 | (0.91–7.19) | 2.93 | (0.98–8.76) | ||||||
| Q3 [3.56–5.49] | 26 | 1.73 | (0.89–3.35) | 1.90 | (0.90–3.98) | 16 | 1.58 | (0.70–3.58) | 1.63 | (0.64–4.15) | 10 | 1.84 | (0.63–5.34) | 2.38 | (0.77–7.38) | ||||||
| Q4 ≥5.49 | 37 | 2.22 | (1.18–4.20) | 2.19 | (1.05–4.56) | 24 | 2.20 | (1.01–4.80) | 2.26 | (0.89–5.69) | 13 | 2.26 | (0.83–6.16) | 2.22 | (0.76–6.52) | ||||||
| Total testosterone, ng/mL | |||||||||||||||||||||
| For 1 SD log | 106 | 0.93 | (0.76–1.14) | 0.49 | 0.91 | (0.72–1.15) | 0.42 | 67 | 0.91 | (0.72–1.15) | 0.44 | 0.89 | (0.67–1.18) | 0.42 | 39 | 0.95 | (0.68–1.33) | 0.76 | 0.93 | (0.65–1.40) | 0.69 |
| Q1 <0.23 | 34 | 1 | [reference] | 0.76 | 1 | [reference] | 0.33 | 22 | 1 | [reference] | 0.60 | 1 | [reference] | 0.42 | 12 | 1 | [reference] | 0.77 | 1 | [reference] | 0.61 |
| Q2 [0.23–0.33] | 21 | 0.71 | (0.39–1.30) | 0.67 | (0.36–1.26) | 12 | 0.61 | (0.28–1.31) | 0.56 | (0.25–1.27) | 9 | 0.98 | (0.38–2.55) | 0.98 | (0.35–2.70) | ||||||
| Q3 [0.33–0.45] | 25 | 1.03 | (0.56–1.87) | 0.95 | (0.49–1.85) | 17 | 0.98 | (0.49–1.98) | 0.95 | (0.42–2.14) | 8 | 0.81 | (0.30–2.22) | 0.85 | (0.31–2.29) | ||||||
| Q4 ≥0.45 | 26 | 0.83 | (0.47–1.47) | 0.70 | (0.37–1.32) | 16 | 0.73 | (0.36–1.48) | 0.61 | (0.26–1.40) | 10 | 0.92 | (0.38–2.24) | 0.81 | (0.31–2.08) | ||||||
*
Including 67 CHD and 39 stroke events.
†
P value for continuous variable and P for trend for variable in quartiles.
‡
Model adjusted for study center, BMI, diabetes, hypertension, hypercholesterolemia, and smoking status.